0001415889-22-012358.txt : 20221209
0001415889-22-012358.hdr.sgml : 20221209
20221209203407
ACCESSION NUMBER: 0001415889-22-012358
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221207
FILED AS OF DATE: 20221209
DATE AS OF CHANGE: 20221209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nielsen Jack
CENTRAL INDEX KEY: 0001602402
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39450
FILM NUMBER: 221455993
MAIL ADDRESS:
STREET 1: C/O AKEBIA THERAPEUTICS, INC.
STREET 2: 245 FIRST STREET, SUITE 1100
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc.
CENTRAL INDEX KEY: 0001802665
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 822279923
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 630 W GERMANTOWN PIKE
STREET 2: SUITE 215
CITY: PLYMOUTH MEETING
STATE: PA
ZIP: 19462
BUSINESS PHONE: (484) 539-9800
MAIL ADDRESS:
STREET 1: 630 W GERMANTOWN PIKE
STREET 2: SUITE 215
CITY: PLYMOUTH MEETING
STATE: PA
ZIP: 19462
4
1
form4-12102022_011258.xml
X0306
4
2022-12-07
0001802665
Harmony Biosciences Holdings, Inc.
HRMY
0001602402
Nielsen Jack
C/O HARMONY BIOSCIENCES HOLDINGS, INC.
630 W GERMANTOWN PIKE, SUITE 215
PLYMOUTH MEETING
PA
19462
true
false
false
false
Common Stock
2022-12-07
4
S
0
64026
60.35
D
2620583
I
See Footnote
Common Stock
2022-12-08
4
S
0
36878
59.90
D
2583705
I
See Footnote
Common Stock
2022-12-09
4
S
0
9847
59.89
D
2573858
I
See Footnote
The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2022.
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $59.93 to $60.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (2) to this Form 4.
The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $59.88 to $60.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $59.88 to $60.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.
/s/ Christian Ulrich, Attorney-in-Fact
2022-12-09